Using positron emission tomography 2-deoxy-2-[18F]fluoro-D-glucose, 11CO, and 15O-water for monitoring androgen independent prostate cancer.

Abstract

PURPOSE:

Monitoring of androgen independent prostate cancer (AIPC) therapy involves monitoring prostate specific antigen (PSA) blood serum concentrations; however, the reliability of small changes in PSA values has been questioned. We performed a small pilot study to determine whether PET might be a useful monitor of changes during anti-angiogenic therapy in AIPC.

PROCEDURES:

Changes in tumor blood flow ([15O] water), blood volume ([11C]CO), 2-deoxy-2-[18F]fluoro-D-glucose (FDG) uptake and metabolic volume were measured before and during thalidomide treatment and compared with changes in PSA in six patients with AIPC.

RESULTS:

The percent change in PSA correlated with the FDG Delta%SUV(mean) (r=0.94, P<0.01) and Delta%metabolic tumor volume (r=0.91, P<0.01) but less well with Delta%blood volume (r=0.65, P=0.14). Percent change blood flow values showed an inverse correlation with percent changes in PSA (r=-0.83, P=0.032).

CONCLUSIONS:

PET measures of tumor blood flow and metabolism may have use in monitoring the physiologic changes occurring during anti-angiogenic therapy in AIPC.

• Authors: Karen A Kurdziel, William D Figg, Jorge A Carrasquillo, Susan Huebsch, Millie Whatley, David Sellers, Steven K Libutti, James M Pluda, William Dahut, Edward Reed, Stephen L Bacharach
• Journal: Molecular imaging and biology (Mol Imaging Biol) 2003 Mar-Apr Vol. 5 Issue 2 Pg. 86-93 ISSN: 1536-1632 [Print] United States
• PMID: 14499149 (Publication Type: Clinical Trial, Clinical Trial, Phase II, Journal Article)

Chemical References

• Androgens
• Antineoplastic Agents
• Carbon Radioisotopes
• Oxygen Radioisotopes
• Radiopharmaceuticals
• Water
• Fluorodeoxyglucose F18
• Thalidomide
• Carbon Monoxide
• Glucose

Topics

• Aged
• Androgens (physiology)
• Antineoplastic Agents (adverse effects, therapeutic use)
• Carbon Monoxide
• Carbon Radioisotopes
• Fluorodeoxyglucose F18 (pharmacokinetics)
• Glucose (metabolism)
• Humans
• Male
• Middle Aged
• Oxygen Radioisotopes
• Prostatic Neoplasms (diagnostic imaging, metabolism)
• Radiopharmaceuticals (pharmacokinetics)
• Thalidomide (adverse effects, therapeutic use)
• Tomography, Emission-Computed (methods)
• Water (metabolism)